Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02897128
Other study ID # 207638
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2016
Est. completion date January 15, 2021

Study information

Verified date July 2021
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Wound complications after sarcoma resection are frequent and potentially devastating problem. The burden of surgical wound complications in the lower extremity after preoperative external beam radiation therapy (EBRT) for soft tissue sarcoma is estimated at 43%. A noninvasive method of predicting complications would be extremely beneficial. The aim of this study is to evaluate the relationship between preoperative skin oxygenation and wound outcomes in a multi-center prospective analysis. This information could lead to a change in practice regarding surgical timing and adjunctive interventions to improve wound healing outcomes.


Description:

It is estimated that there are 11,400 new cases of soft tissue sarcoma diagnosed in the United States annually. Most high-grade sarcomas, and other selected low or intermediate grade sarcomas, are treated with a limb salvage surgical resection in conjunction with external beam radiation to optimize local control. The current preference of most practicing orthopaedic/surgical oncologists and radiation oncologists is to implement the radiation treatments prior to surgery to diminish the total radiation dose and field size, thereby optimizing long-term functional results of the salvaged limb. While there are clear advantages of preoperative radiation, there are well-demonstrated negative consequences with regard to healing of the surgical wound. Currently there are no reliable clinical criteria to aid physicians in determining an individual patient's risk of developing a postoperative wound complication. This fact, combined with the rarity of the sarcoma diagnosis, has prevented improvement in wound outcomes in sarcoma patients. This project is designed to close this critical gap in knowledge. The investigators propose utilizing a preoperative measurement of transcutaneous oxygen (Tc02) at the proposed incision to classify patients into high- and low-risk categories for development of wound complications after resection. Measurement of preoperative TcO2 represents a novel application of a simple, noninvasive method by which to assess skin oxygenation. Given the results of an already completed pilot investigation (Nystrom 2016), the investigators believe that this important clinical problem is well suited for a prospective, multi-disciplinary, multi-institutional investigation. A successful project would result in an enhanced ability to identify wounds at risk prior to surgery and allow for additional investigation into perioperative interventions (delay of surgery until recovery of oxygenation, increasing suture duration, judicious use of muscle flaps and skin grafts, postoperative hyperbaric oxygen, or treatment with incisional wound vacuum-assisted closure) that may mitigate this significant adverse outcome.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date January 15, 2021
Est. primary completion date September 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age > 18 - biopsy proven soft tissue sarcoma of the lower extremity (pelvic area and below) - plan for preoperative radiation and limb sparing resection Exclusion Criteria: - upper extremity sarcoma - recurrent soft tissue sarcoma - prior surgery in the area of the sarcoma - prior radiation in the area of the sarcoma - need for immediate skin graft or flap for coverage - pregnant patients - patients unwilling to have surgery or radiation

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational Only - Transcutaneous Oxygen Measurement
The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio
United States University of Florida Gainesville Florida
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of Oklahoma Oklahoma City Oklahoma

Sponsors (6)

Lead Sponsor Collaborator
The Cleveland Clinic Musculoskeletal Tumor Society, Orthopedic Research and Education Foundation, University of Florida, University of Iowa, University of Oklahoma

Country where clinical trial is conducted

United States, 

References & Publications (2)

Nystrom LM, Miller BJ. Transcutaneous Oximetry May Predict Wound Healing Complications In Preoperatively Radiated Soft Tissue Sarcoma. Iowa Orthop J. 2016;36:117-22. — View Citation

O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002 Jun 29;359(9325):2235-41. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Wound healing Your wound will be assessed clinically for evidence of healing or any wound complication (ie. infection, dehiscence, seroma). 120 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03985722 - Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients Phase 1
Withdrawn NCT02464332 - Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery Phase 1
Completed NCT00243685 - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase 2/Phase 3
Completed NCT00289809 - TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients Phase 1/Phase 2
Active, not recruiting NCT01185964 - A Study of IMC-3G3 in Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT00753688 - Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Phase 3
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Completed NCT00187174 - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors Phase 1
Completed NCT03798795 - Radiomics for Tumor Grading of Soft Tissue Sarcomas.
Terminated NCT02929394 - Trabectedin Maintenance Post 1st-line in STS Phase 3
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Completed NCT00406601 - BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas Phase 2
Completed NCT00297258 - Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Phase 2
Active, not recruiting NCT06114173 - Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma Early Phase 1
Completed NCT00061659 - Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Recruiting NCT03815474 - Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT02812654 - Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment Phase 2
Completed NCT00204620 - Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS) Phase 2
Completed NCT03058406 - A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Active, not recruiting NCT02415816 - Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas N/A